Administration of ketamine for unipolar and bipolar depression

  title={Administration of ketamine for unipolar and bipolar depression},
  author={Christoph Kraus and Ulrich Rabl and Thomas Vanicek and Laura Carlberg and Ana Popovic and Marie Spies and Lucie Bartova and Gregor Gryglewski and Konstantinos Papageorgiou and Rupert Lanzenberger and Matth{\"a}us Willeit and Dietmar Winkler and Janusz K. Rybakowski and Siegfried Kasper},
  journal={International Journal of Psychiatry in Clinical Practice},
  pages={12 - 2}
  • C. Kraus, U. Rabl, S. Kasper
  • Published 2 January 2017
  • Psychology
  • International Journal of Psychiatry in Clinical Practice
Abstract Objective: Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile. Methods: Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science. Results: Randomized, placebo-controlled or open-label trials reported antidepressant response rates after 24… 
Ketamine for Bipolar Depression: A Systematic Review
Some preliminary evidence supporting use of intravenous racemic ketamine to treat adults with bipolar depression is found, with Ketamine was reasonably well tolerated; however, 2 participants developed manic symptoms.
Ketamine for Depression, 2: Diagnostic and Contextual Indications.
  • C. Andrade
  • Psychology
    The Journal of clinical psychiatry
  • 2017
Diagnostic indications for the off-label use of ketamine as an antidepressant and possible contexts in which ketamine may be trialled are examined.
Adjunctive treatment with psychostimulants and stimulant-like drugs for resistant bipolar depression: a systematic review and meta-analysis
Treatment guidelines should be revised to include these medications earlier in the therapeutic algorithm for resistant acute bipolar depression, as LDX, modafinil, and armodafinIL seem to offer a reasonably well-tolerated and safe treatment in resistant bipolar depression.
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder.
Only ketamine appeared to be more efficacious than placebo 24 hours after infusion for response rate and depression rating scale scores, and the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder was reviewed.
Ketamine and Treatment-Resistant Depression.
Evidence from 10 systematic reviews and randomized controlled trials suggest that most of the researchers concluded ketamine significantly decreased depression severity ratings at short-term assessment intervals, whereas evidence examining the long-term effects is lacking.


A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
[Factors connected with efficacy of single ketamine infusion in bipolar depression].
A rapid antidepressant effect of ketamine infusion maintaining for 2 weeks is confirmed, in a considerable proportion of patients with bipolar depression, and good clinical tolerance of such procedure is shown.
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
In this relatively large group of patients with TRD, ketamine was safe and well tolerated and further research investigating the safety of ketamine in severe and refractory depression is warranted.
Rapid Antidepressant Response with Ketamine: Is it the Solution to Resistant Depression?
The ketamine infusion was effective in reducing the HDRS scores, and the change remained significant from minute 80 to day 3 postinfusion at each time point, but the change was not significant at any time after day 3.
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving the understanding of ketamines' mechanism of action.
Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial
The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.
Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
A substantial relationship between ketamine's antidepressant and psychotomimetic effects was found, and this relationship could be mediated by the initial steps of ketamine’s action, trough NMDA receptors, shared by both ketamines' clinical effects.